Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Beneish M-Score: -2.01 (As of Jul. 24, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600513 Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
65 GF Score
Price ¥15.42
GF Value ¥13.72
Valuation Modestly Overvalued
! 10 Warning Signs
View Full Analysis

What is Jiangsu Lianhuan Pharmaceutical Co Beneish M-Score?

Jiangsu Lianhuan Pharmaceutical Co SHSE:600513 -6.94% 65 Beneish M-Score is -2.01 as of Jul. 24, 2026. GuruFocus rates SHSE:600513 with a GF Score™ of 65/100 and a GF Value™ of ¥13.72 (Modestly Overvalued). The stock has 10 warning signs investors should review. Among 910 Drug Manufacturers companies, Jiangsu Lianhuan Pharmaceutical Co ranks worse than 78.46% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.01 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score or its related term are showing as below:

SHSE:600513' s Beneish M-Score Range Over the Past 10 Years
Min: -2.62   Med: -2.26   Max: -1.66
Current: -2.01

During the past 13 years, the highest Beneish M-Score of Jiangsu Lianhuan Pharmaceutical Co was -1.66. The lowest was -2.62. And the median was -2.26.


Jiangsu Lianhuan Pharmaceutical Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jiangsu Lianhuan Pharmaceutical Co Beneish M-Score Chart

Jiangsu Lianhuan Pharmaceutical Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.56 -2.36 -2.41 -2.16 -2.00

Jiangsu Lianhuan Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.91 -1.98 -1.66 -2.00 -2.01

SHSE:600513 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Lianhuan Pharmaceutical Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score falls into.


SHSE:600513
65GF Score
Jiangsu Lianhuan Pharmaceutical Co Ltd SHSE:600513
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Jiangsu Lianhuan Pharmaceutical Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Jiangsu Lianhuan Pharmaceutical Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9644+0.528 * 1.5226+0.404 * 1.1427+0.892 * 1.281+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.6074+4.679 * -0.017957-0.327 * 1.184
=-2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥836 Mil.
Revenue was 810.626 + 629.399 + 797.117 + 657.637 = ¥2,895 Mil.
Gross Profit was 214.999 + 225.4 + 219.504 + 238.248 = ¥898 Mil.
Total Current Assets was ¥1,981 Mil.
Total Assets was ¥4,156 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,529 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥498 Mil.
Total Current Liabilities was ¥2,116 Mil.
Long-Term Debt & Capital Lease Obligation was ¥325 Mil.
Net Income was 6.425 + -63.27 + 4.966 + -63.088 = ¥-115 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was -78.955 + 158.411 + -15.072 + -104.714 = ¥-40 Mil.
Total Receivables was ¥676 Mil.
Revenue was 627.706 + 515.879 + 518.239 + 597.88 = ¥2,260 Mil.
Gross Profit was 260.481 + 246.158 + 246.419 + 314.446 = ¥1,068 Mil.
Total Current Assets was ¥1,738 Mil.
Total Assets was ¥3,624 Mil.
Property, Plant and Equipment(Net PPE) was ¥1,391 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥640 Mil.
Total Current Liabilities was ¥1,482 Mil.
Long-Term Debt & Capital Lease Obligation was ¥316 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(835.515 / 2894.779) / (676.267 / 2259.704)
=0.288628 / 0.299272
=0.9644

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1067.504 / 2259.704) / (898.151 / 2894.779)
=0.472409 / 0.310266
=1.5226

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1980.727 + 1528.646) / 4156.499) / (1 - (1738.436 + 1391.443) / 3623.582)
=0.15569 / 0.136247
=1.1427

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2894.779 / 2259.704
=1.281

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 1391.443)) / (0 / (0 + 1528.646))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(498.086 / 2894.779) / (640.101 / 2259.704)
=0.172064 / 0.283268
=0.6074

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((324.809 + 2116.22) / 4156.499) / ((315.759 + 1481.546) / 3623.582)
=0.58728 / 0.496002
=1.184

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-114.967 - 0 - -40.33) / 4156.499
=-0.017957

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Jiangsu Lianhuan Pharmaceutical Co has a M-score of -2.01 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.01 mean?
Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) has a Beneish M-Score of -2.01 as of Jul. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. According to the industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #714 out of 910 companies in the Drug Manufacturers industry, placing it in the top 78.5%.
Is Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score too high?
Jiangsu Lianhuan Pharmaceutical Co's current Beneish M-Score is -2.01. Based on the distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #714 out of 910 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Lianhuan Pharmaceutical Co has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Lianhuan Pharmaceutical Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Lianhuan Pharmaceutical Co ranks #714 out of 910 companies for Beneish M-Score. This places Jiangsu Lianhuan Pharmaceutical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Jiangsu Lianhuan Pharmaceutical Co and its competitors. Jiangsu Lianhuan Pharmaceutical Co's current Beneish M-Score is -2.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Lianhuan Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥13.72, compared to a current price of ¥15.42 — trading 12.4% above its estimated fair value. The current Beneish M-Score is -2.01. Jiangsu Lianhuan Pharmaceutical Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513), the current Beneish M-Score is -2.01 as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Jiangsu Lianhuan Pharmaceutical Co (SHSE:600513) Overvalued in 2026?

Based on GuruFocus' analysis, Jiangsu Lianhuan Pharmaceutical Co stock appears to be overvalued. The current stock price of ¥15.42 is trading 12.4% above its estimated GF Value™ of ¥13.72. GuruFocus considers Jiangsu Lianhuan Pharmaceutical Co to be Modestly Overvalued.

Key valuation signals for SHSE:600513:

  • Beneish M-Score: -2.01
  • GF Value™: ¥13.72 vs. price of ¥15.42 (12.4% above fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the SHSE:600513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Jiangsu Lianhuan Pharmaceutical Co Business Description

Address No. 9, Jiankang 1st Road, Yangzhou Bio-Health Industry Park, Jiangsu Province, Yangzhou, Jiangsu, CHN, 225127
Jiangsu Lianhuan Pharmaceutical Co Ltd is engaged in producing benign prostatic hyperplasia, allergy and cardiovascular drugs. In the field of pharmaceutical manufacturing, the company's main products include several series such as urinary system drugs, antihistamines, cardiovascular drugs, steroid hormones, antibiotics, etc., covering chemical raw materials and injections, solid preparations and various drug dosage forms, including the national first-class new drug Apelite Tablets (Chuanliu).
65GF Score

Get the complete analysis for SHSE:600513

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.42
Price
¥13.72
GF Value